Sunesis Pharmaceuticals, Inc. [SNSS] took an upward turn with a change of 10.78%, trading at the price of $0.82 during the trading session on Thursday. The price movement in correlation with percentage of the mentioned increase can allow a valuable insight to investors. During the last trading session 988952 shares changed hands being bought and sold, while Sunesis Pharmaceuticals, Inc. shares have an average trading volume of 2.17M shares for that time period. SNSS monthly volatility recorded 13.89%, in the meanwhile having share price volatility for the week set at 16.35%. PS value for SNSS stocks is with PB recorded at 3.68.
Sunesis Pharmaceuticals, Inc. [NASDAQ:SNSS]: Analyst Rating and Earnings
Its stock price has been found in the range of 0.20 to 1.77. This is compared to its latest closing price of $0.74.
Pay attention to the next-scheduled financial results for this company to be released, which is slated for Thu 5 Mar (In 20 Days).
Fundamental Analysis of Sunesis Pharmaceuticals, Inc. [SNSS]
Now let’s turn to look at profitability: with a current Operating Margin for Sunesis Pharmaceuticals, Inc. [SNSS] sitting at -10848.10.
This company’s Return on Total Capital is -128.11, and its Return on Invested Capital has reached 267.80%. Its Return on Equity is -208.44, and its Return on Assets is -107.19. These metrics suggest that this Sunesis Pharmaceuticals, Inc. does a poor job of managing its assets, and likely won’t be able to provide successful business outcomes for its investors in the near term.
Turning to investigate this organization’s capital structure, Sunesis Pharmaceuticals, Inc. [SNSS] has generated a Total Debt to Total Equity ratio of 185.22. Similarly, its Total Debt to Total Capital is 64.94, while its Total Debt to Total Assets stands at 48.26.
What about valuation? This company’s Enterprise Value to EBITDA is -2.05. Total Debt to Enterprise Value stands at 0.25.
Shifting the focus to workforce efficiency, Sunesis Pharmaceuticals, Inc. [SNSS] earns $8,172 for each employee under its payroll. Similarly, this company’s Total Asset Turnover is 0.01. This publicly-traded organization’s liquidity data is also interesting: its Quick Ratio is 1.34 and its Current Ratio is 1.34. This company, considering these metrics, has a healthy ratio between its short-term liquid assets and its short-term liabilities, making it a less risky investment.
Sunesis Pharmaceuticals, Inc. [SNSS] has 114.25M shares outstanding, amounting to a total market cap of $84.07M. Its stock price has been found in the range of 0.20 to 1.77. At its current price, it has moved down by -53.95% from its 52-week high, and it has moved up 317.79% from its 52-week low.
This stock’s Beta value is currently 2.83, which indicates that it is 16.35% more volatile that the wider market. This stock’s Relative Strength Index (RSI) is at 77.92. This RSI suggests that Sunesis Pharmaceuticals, Inc. is currently Overbought.
Conclusion: Is Sunesis Pharmaceuticals, Inc. [SNSS] a Reliable Buy?
Shares of Sunesis Pharmaceuticals, Inc. [SNSS], overall, appear to be a solid investment option, with Wall Street analysts expecting its price to rise considerably in the next 12 months. This company generates high value from the labor resources and other capital it has available, and while it has heavy Long-Term Debt to Equity, the majority of the metrics point to this investment being highly attractive.